CORE TECHNOLOGY
RGVax is a chimeric HPV virus-like particle (VLP) platform that displays 360 copies of the highly conserved, neutralizing HPV epitope (RG1). Animal vaccination studies confirmed broad-spectrum protection (via RG-1 cross-neutralizing antibodies) against clinically relevant 27 HPVs. This dramatic improvement over licensed HPV vaccines led to a National Cancer Institute (NCI) PREVENT contract that funds GMP, toxicology, IND, and initiation for Phase 1.
PathoVax is preparing for a Phase I clinical assessment(s) of the RGVax commercial formulation that should establish human proof of concept for broad efficacy and comparable, if not superior, human responsiveness as compared current vaccines in the market.
Scientific Publications
.
Olczak P, Matsui K, Wong M, Alvarez J, Lambert P, Christensen ND, Hu J, Huber B, Kirnbauer R, Wang JW, Roden RBS. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer. J Virol. 2022 Jul 13;96(13):e0056622. doi: 10.1128/jvi.00566-22. Epub 2022 Jun 15. PMID: 35703545; PMCID: PMC9278150.
Schellenbacher C, Huber B, Skoll M, Shafti-Keramat S, Roden RBS, Kirnbauer R. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity. Vaccine. 2019 Jun 12;37(27):3529-3534. doi: 10.1016/j.vaccine.2019.05.011. Epub 2019 May 27. PMID: 31147274; PMCID: PMC6832690.
Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018 Apr;18(4):240-254. doi: 10.1038/nrc.2018.13. Epub 2018 Mar 2. PMID: 29497146; PMCID: PMC6454884.
Abstract LB-200: A cGMP-grade chimeric papillomavirus candidate vaccine (HPV16 RG1-VLP) confers long term cross-protection compared to a nonavalent hpv vaccine in a pre-clinical papillomavirus animal model Cancer Res (2019) 79 (13_Supplement): LB-200.
Abstract 2367: cGMP production of a chimeric virus-like particle vaccine for prevention of HPV-associated cancers Cancer Res (2016) 76 (14_Supplement): 2367.
Wang JW, Roden RB. L2, the minor capsid protein of papillomavirus. Virology. 2013 Oct;445(1-2):175-86. doi: 10.1016/j.virol.2013.04.017. Epub 2013 May 17. PMID: 23689062; PMCID: PMC3770800.
Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RBS, Kirnbauer R. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol. 2013 Dec;133(12):2706-2713. doi: 10.1038/jid.2013.253. Epub 2013 May 10. PMID: 23752042; PMCID: PMC3826974.
Schellenbacher C, Roden R, Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol. 2009 Oct;83(19):10085-95. doi: 10.1128/JVI.01088-09. Epub 2009 Jul 29. PMID: 19640991; PMCID: PMC2748020.